NCT06998264 In-depth Analysis of the Immune Responses in the Upper Respiratory Tract of Influenza-infected Children
| NCT ID | NCT06998264 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Geneva |
| Condition | Influenza Infection |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-03-04 |
| Primary Completion | 2026-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2025-03-04 with a primary completion date of 2026-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The NoseFlu-Kids project aims at characterizing the immune response in the upper respiratory tract in children aged 2 to 5 with a laboratory-confirmed influenza infection. The immune response during the acute phase of the infection and after recovery will be compared to that of control children with no infection or vaccinated with the inactivated flu vaccine by the nasal route (recruited as part of a mirror study in Oxford). The primary objective of this observational study is to quantify the inflammatory response in the nasal cavity and to correlate it with viral load and with clinical parameters. The study also aims to compare the inflammatory response measured in the nose to that measured in the blood. Participants will have two study visits including a blood draw, several nasal samplings (nasal lining fluid and nasal cells) and a saliva sampling, one within 72 hours of their hospital admission and another one month later. Nasal lining fluid and saliva will be obtained every two or three days until symptoms disappear. During those visits, questions regarding symptoms will be asked.
Eligibility Criteria
Inclusion criteria: * Aged 2-5 years * Presenting clinical signs of an influenza-like illness * Having a concomitant positive laboratory test for influenza. Exclusion criteria: * Immunosuppression * Intubation or under invasive mechanical ventilation * Co-infection with RSV or SARS-CoV-2
Contact & Investigator
Arnaud Didierlaurent, PhD
PRINCIPAL INVESTIGATOR
University of Geneva, Switzerland
Frequently Asked Questions
Who can join the NCT06998264 clinical trial?
This trial is open to participants of all sexes, aged 2 Years or older, up to 5 Years, studying Influenza Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06998264 currently recruiting?
Yes, NCT06998264 is actively recruiting participants. Contact the research team at jennifer.villers@hug.ch for enrollment information.
Where is the NCT06998264 trial being conducted?
This trial is being conducted at Geneva, Switzerland.
Who is sponsoring the NCT06998264 clinical trial?
NCT06998264 is sponsored by University Hospital, Geneva. The principal investigator is Arnaud Didierlaurent, PhD at University of Geneva, Switzerland. The trial plans to enroll 40 participants.